homepage-top-section

First announced last month, the move aims to advance Gilead’s oncology portfolio. Under the agreement, the company acquired all outstanding equity of Tubulis for $3.15bn upfront on a

The initiative will embed agentic capabilities throughout BMS’ research, clinical, manufacturing, commercial, and corporate operations. It aims to shift from basic conversational AI towards advanced agentic tools within

The move aims to allow pharmaceutical and biotechnology researchers to use AI more effectively by leveraging enhanced bioinformatics tools and curated knowledge bases. The integration also aims to

Helicons are stabilised, cell-penetrant alpha-helical peptides engineered to interact with intracellular protein targets, including those with flat surfaces unsuitable for traditional small molecule engagement. The partnership will investigate

Data from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials support these approvals. They cover the use of Enhertu in both the neoadjuvant and adjuvant treatment settings for adult

Affecting adults and children, this rare, progressive, genetic disorder impacts both bone and muscle health due to the body’s inability to retain sufficient phosphorus, a mineral essential for

The offer was approved by Assertio’s Board of Directors, following a revised merger agreement process and is considered a “superior proposal” compared to the previous agreement with Garda

The approval is intended for adults with PsA who have had inadequate response or intolerance to previous disease-modifying antirheumatic drug (DMARD) therapy. Sotyktu can be used alone or

The acquisition has been approved unanimously by both companies’ boards of directors, with the transaction expected to close in the third quarter of 2026. Angelini Pharma will purchase